185 related articles for article (PubMed ID: 37407886)
1. Papillary Renal Cell Carcinoma: A Review of Prospective Clinical Trials.
Maughan BL; Sirohi D
Curr Treat Options Oncol; 2023 Sep; 24(9):1199-1212. PubMed ID: 37407886
[TBL] [Abstract][Full Text] [Related]
2. Management of Atypical Renal Cell Carcinomas.
Liaw BC; Mehrazin R; Baker C; Sfakianos JP; Tsao CK
Curr Treat Options Oncol; 2017 Sep; 18(10):61. PubMed ID: 28913767
[TBL] [Abstract][Full Text] [Related]
3. Non-clear cell renal cell carcinomas: biological insights and therapeutic challenges and opportunities.
Malouf GG; Joseph RW; Shah AY; Tannir NM
Clin Adv Hematol Oncol; 2017 May; 15(5):409-418. PubMed ID: 28591094
[TBL] [Abstract][Full Text] [Related]
4. Papillary renal cell carcinoma: current and controversial issues.
Angori S; Lobo J; Moch H
Curr Opin Urol; 2022 Jul; 32(4):344-351. PubMed ID: 35674688
[TBL] [Abstract][Full Text] [Related]
5. Advanced papillary renal cell carcinoma: Epidemiology, genomic drivers, current therapies, and ongoing trials.
Sweeney PL; Jang A; Halat SK; Pal SK; Barata PC
Cancer Treat Res Commun; 2022; 33():100639. PubMed ID: 36162322
[TBL] [Abstract][Full Text] [Related]
6. The molecular characterization and therapeutic strategies of papillary renal cell carcinoma.
Chen Q; Cheng L; Li Q
Expert Rev Anticancer Ther; 2019 Feb; 19(2):169-175. PubMed ID: 30474436
[No Abstract] [Full Text] [Related]
7. Checkpoint inhibitors in metastatic papillary renal cell carcinoma.
de Vries-Brilland M; McDermott DF; Suárez C; Powles T; Gross-Goupil M; Ravaud A; Flippot R; Escudier B; Albigès L
Cancer Treat Rev; 2021 Sep; 99():102228. PubMed ID: 34111642
[TBL] [Abstract][Full Text] [Related]
8. Papillary renal cell carcinoma: A review of the current therapeutic landscape.
Courthod G; Tucci M; Di Maio M; Scagliotti GV
Crit Rev Oncol Hematol; 2015 Oct; 96(1):100-12. PubMed ID: 26052049
[TBL] [Abstract][Full Text] [Related]
9. Toward Biological Subtyping of Papillary Renal Cell Carcinoma With Clinical Implications Through Histologic, Immunohistochemical, and Molecular Analysis.
Saleeb RM; Brimo F; Farag M; Rompré-Brodeur A; Rotondo F; Beharry V; Wala S; Plant P; Downes MR; Pace K; Evans A; Bjarnason G; Bartlett JMS; Yousef GM
Am J Surg Pathol; 2017 Dec; 41(12):1618-1629. PubMed ID: 28984673
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Cabozantinib for Papillary Compared With Clear-cell Renal Cell Carcinoma Following Immune Checkpoint Inhibitor Treatment.
Tachibana H; Inakawa T; Nemoto Y; Ishihara H; Fukuda H; Yoshida K; Iizuka J; Hashimoto Y; Tanabe K; Kondo T; Takagi T
Anticancer Res; 2022 Jun; 42(6):3151-3158. PubMed ID: 35641290
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma.
Kroeze SG; Bijenhof AM; Bosch JL; Jans JJ
Cancer Biomark; 2010; 7(6):261-8. PubMed ID: 21694464
[TBL] [Abstract][Full Text] [Related]
12. Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study.
de Vries-Brilland M; Gross-Goupil M; Seegers V; Boughalem E; Beuselinck B; Thibault C; Chevreau C; Ladoire S; Barthélémy P; Negrier S; Borchiellini D; Huillard O; Geoffrois L; Gravis G; Saldana C; Thiery-Vuillemin A; Escudier B; Ravaud A; Albiges L
Eur J Cancer; 2020 Sep; 136():76-83. PubMed ID: 32653774
[TBL] [Abstract][Full Text] [Related]
13. Rupture of papillary renal cell carcinoma.
Hora M; Hes O; Klecka J; Boudová L; Chudácek Z; Kreuzberg B; Michal M
Scand J Urol Nephrol; 2004; 38(6):481-4. PubMed ID: 15841782
[TBL] [Abstract][Full Text] [Related]
14. Integrated Phenotypic/Genotypic Analysis of Papillary Renal Cell Carcinoma Subtypes: Identification of Prognostic Markers, Cancer-related Pathways, and Implications for Therapy.
Saleeb RM; Plant P; Tawedrous E; Krizova A; Brimo F; Evans AJ; Wala SJ; Bartlett J; Ding Q; Boles D; Rotando F; Farag M; Yousef GM
Eur Urol Focus; 2018 Sep; 4(5):740-748. PubMed ID: 28753789
[TBL] [Abstract][Full Text] [Related]
15. [Diagnostic value of mult-detector CT for papillary renal cell carcinoma and chromophobe renal cell carcinoma].
Liu X; Zou X; Chen H; Fang X; Hu X; Sun R
Zhonghua Zhong Liu Za Zhi; 2015 Jan; 37(1):52-6. PubMed ID: 25877320
[TBL] [Abstract][Full Text] [Related]
16. Distinct Genomic Copy Number Alterations Distinguish Mucinous Tubular and Spindle Cell Carcinoma of the Kidney From Papillary Renal Cell Carcinoma With Overlapping Histologic Features.
Ren Q; Wang L; Al-Ahmadie HA; Fine SW; Gopalan A; Sirintrapun SJ; Tickoo SK; Reuter VE; Chen YB
Am J Surg Pathol; 2018 Jun; 42(6):767-777. PubMed ID: 29462091
[TBL] [Abstract][Full Text] [Related]
17. Papillary renal cell carcinoma with cytologic and molecular genetic features overlapping with renal oncocytoma: Analysis of 10 cases.
Michalova K; Steiner P; Alaghehbandan R; Trpkov K; Martinek P; Grossmann P; Montiel DP; Sperga M; Straka L; Prochazkova K; Cempirkova D; Horava V; Bulimbasic S; Pivovarcikova K; Daum O; Ondic O; Rotterova P; Michal M; Hora M; Hes O
Ann Diagn Pathol; 2018 Aug; 35():1-6. PubMed ID: 30072012
[TBL] [Abstract][Full Text] [Related]
18. Cystic and necrotic papillary renal cell carcinoma: prognosis, morphology, immunohistochemical, and molecular-genetic profile of 10 cases.
Peckova K; Martinek P; Pivovarcikova K; Vanecek T; Alaghehbandan R; Prochazkova K; Montiel DP; Hora M; Skenderi F; Ulamec M; Rotterova P; Daum O; Ferda J; Davidson W; Ondic O; Dubova M; Michal M; Hes O
Ann Diagn Pathol; 2017 Feb; 26():23-30. PubMed ID: 28038707
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?
Martinez Chanza N; Tripathi A; Harshman LC
Curr Treat Options Oncol; 2019 May; 20(5):44. PubMed ID: 31054006
[TBL] [Abstract][Full Text] [Related]
20. The Changing Landscape of Management of Metastatic Renal Cell Carcinoma: Current Treatment Options and Future Directions.
Salgia NJ; Dara Y; Bergerot P; Salgia M; Pal SK
Curr Treat Options Oncol; 2019 Apr; 20(5):41. PubMed ID: 30937639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
